Zentalis Pharmaceuticals/ZNTL

$11.33

0.44%
-
1D1W1MYTD1YMAX

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Ticker

ZNTL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kimberly Blackwell

Employees

168

Headquarters

New york, United States

ZNTL Metrics

BasicAdvanced
$851M
Market cap
-
P/E ratio
-$3.36
EPS
1.83
Beta
-
Dividend rate
$851M
1.82649
$31.46
$9.56
777K
20.975
22.08%

What the Analysts think about ZNTL

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
194.79% upside
High $50.00
Low $15.00
$11.33
Current price
$33.40
Average price target

ZNTL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
24.69% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$41M
∞%
Net income
$10M
-116.42%
Profit margin
24.69%
∞%

ZNTL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 118.26%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.85
-$0.79
-$0.93
$0.14
-
Expected
-$1.04
-$0.91
-$0.92
-$0.77
-$0.86
Surprise
78.31%
-13.35%
1.54%
-118.26%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Zentalis Pharmaceuticals stock?

Zentalis Pharmaceuticals (ZNTL) has a market cap of $801M as of May 25, 2024.

What is the P/E ratio for Zentalis Pharmaceuticals stock?

The price to earnings (P/E) ratio for Zentalis Pharmaceuticals (ZNTL) stock is 0 as of May 25, 2024.

Does Zentalis Pharmaceuticals stock pay dividends?

No, Zentalis Pharmaceuticals (ZNTL) stock does not pay dividends to its shareholders as of May 25, 2024.

When is the next Zentalis Pharmaceuticals dividend payment date?

Zentalis Pharmaceuticals (ZNTL) stock does not pay dividends to its shareholders.

What is the beta indicator for Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (ZNTL) has a beta rating of 1.81. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Zentalis Pharmaceuticals stock price target?

The target price for Zentalis Pharmaceuticals (ZNTL) stock is $33.4, which is 196.36% above the current price of $11.27. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Zentalis Pharmaceuticals stock

Buy or sell Zentalis Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing